EN DE
Watch Rapid Dose Therapeutics Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Rapid Dose Therapeutics Corp (RDTCF) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Rapid Dose Therapeutics Corp stock $0.05, price $0.06, that is 6.0% below the price, quality 23 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Canada · ISIN CA75339A1012

RD Rapid Dose Therapeutics Corp logo Thin data Nov 13, 2026

Rapid Dose Therapeutics Corp

RDTCF · US

The stock is already about fairly priced and weak company.

Get notified free when this changes
Fair value $0.0538 · Fairly valued 
Mixed Growth (revenue 5y +29.7 %/yr in CAD) 
Negative equity (buybacks among others) 
Revenue last quarter 68% below a year ago. 
Quality 23/100 
Loss-making · -148.3% net margin (TTM) 
Negative free cash flow 
Trails peers (2/6) 
Narrow moat 3/100 · thin data
Thin data 
Estimate⚠ Thinly traded
Watch Rapid Dose Therapeutics Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1.11 $0.0004 Fair Value $0.0538 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.

How to read this chart

60‑month range $0.0004 – $1.11 · fair‑value band $0.0464 – $0.0611 · the $0.0572 price screens above the $0.0538 fair value. As of Nov 13, 2026.

Follow Rapid Dose Therapeutics in your weekly email

Every Wednesday you see whether Rapid Dose Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies in Canada.

Show moreShow less

The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system designed to rapidly release pharmaceuticals, emulsified oils, and over-the-counter medicines into the bloodstream.

It also provides over-the-counter products consisting of QuickStrip Energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12; and QuickStrip Sleep to deliver melatonin, as well as dental products including Lidocaine QuickStrip, a muco-adhesive oral thin film.

It also engages in the research, production, provision, and distribution of technical services for the delivery of oral thin film strips containing active ingredients.

In addition, the company is involved in the sale of health and wellness products, such as nutraceuticals; white label manufacturing, including oral thin film strips containing active ingredients under cannabis licensing; and the provision of consulting services for the application of active ingredients with the oral thin film polymer formulation and processes.

Rapid Dose Therapeutics Corp. is headquartered in Burlington, Canada.

Stock analysis

Rapid Dose Therapeutics Corp (RDTCF) currently trades at $0.0572, while our estimate is $0.0538, so the stock looks roughly fairly valued today (gap 6.4%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.0464 (bear) to $0.0611 (bull), the price of $0.0572 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Rapid Dose Therapeutics Corp reported revenue of C$2.8M in FY2026 versus C$1.8M in FY2022, a compound +12.2%/yr. Reported net income was −C$3.4M in FY2026.

Key figures

Market cap $10.0M Micro · P/S ratio 4.71 · EPS (TTM) $−0.0400 · Net margin −122% · Return on equity −914% · Return on assets (EBIT) −46.5% (5-year average) · Operating margin −242% · Revenue (TTM) C$2.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).

What moves the price

The share trades about 62% below its 52-week high and 333% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −6%, RDTCF screens richer than that median.

Fair Value

Bear $0.0464 Fair Value $0.0538 Bull $0.0611
Price $0.0572 · Downside -6.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 23/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 34
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 0
Debt, balance sheet and risk of trouble
Investment 66
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 15
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 16
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+33.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.7%
Start year 2021 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+73.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−235.3% (2021) → −59.8% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch RDTCF, get fair value alerts →

Compare Rapid Dose Therapeutics Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 23 · Bottom 25%
Fair Value upside −5.9% · Top 25%
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −103.3% · Bottom 25%
Net margin (12 months) −148.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −67.8% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 6.73× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)25 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs RDTCF
Genmab A/S GMAB kr 3,448 kr 3,917 +14% vs RDTCF
Samsung Biologics Co 207940 1,411,000 KRW 1,573,000 KRW +11% vs RDTCF
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs RDTCF
argenx SE ARGX $960.04 $908.40 −5% vs RDTCF
CSL Limited CSL A$202.92 A$183.54 −10% vs RDTCF
Moderna, Inc MRNA $223.37 $139.99 −37% vs RDTCF
BeOne Medicines AG 6160 HK$249.80 HK$152.80 −39% vs RDTCF
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs RDTCF
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs RDTCF

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Rapid Dose Therapeutics Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Rapid Dose Therapeutics Corp Fair Value". https://www.fairvalue-calculator.com/stock/RDTCF

Frequently asked questions

Is Rapid Dose Therapeutics Corp (RDTCF) overvalued or undervalued?
As of Nov 13, 2026, our estimate of fair value is $0.0538 versus a price of $0.0572, about 6% lower (fairly valued).
What is the fair value of RDTCF?
Our estimate for Rapid Dose Therapeutics Corp is $0.0538 (as of Nov 13, 2026), built from audited fundamentals. The current price: $0.0572.
What is the quality score of RDTCF?
Rapid Dose Therapeutics Corp has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rapid Dose Therapeutics Corp (RDTCF)?
Our calculated price target is the estimate of $0.0538 (as of Nov 13, 2026). Cautious scenario $0.0464, optimistic scenario $0.0611. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Rapid Dose Therapeutics Corp stock forecast for 2026?
Our estimate puts fair value at $0.0538, about 6% lower versus a price of $0.0572 (fairly valued). Cautious scenario $0.0464, optimistic scenario $0.0611. The calculation is refreshed regularly with new filings.
What is the revenue of Rapid Dose Therapeutics Corp (RDTCF)?
Rapid Dose Therapeutics Corp reported trailing-twelve-month revenue of about C$2.1M (latest available figure, as of Nov 13, 2026).
What is the intrinsic value of Rapid Dose Therapeutics Corp (RDTCF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rapid Dose Therapeutics Corp it is $0.0538 per share (as of Nov 13, 2026), against a price of $0.0572.
Is Rapid Dose Therapeutics Corp stock overvalued or undervalued in 2026?
As of Nov 13, 2026, RDTCF trades above its calculated fair value: price $0.0572, fair value $0.0538, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RDTCF?
No. The price is what the market pays today ($0.0572); the fair value is what the company's own numbers justify ($0.0538). For Rapid Dose Therapeutics Corp the two are $0.0034 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rapid Dose Therapeutics Corp worth?
The market values Rapid Dose Therapeutics Corp at about $10.0M (market capitalisation, as of Nov 13, 2026). Per share that is $0.0572; our models calculate a fair value of $0.0538 per share.
What do the bullish and bearish scenarios say about RDTCF?
Our models span a range for Rapid Dose Therapeutics Corp: cautious scenario $0.0464, base $0.0538, optimistic $0.0611 per share (as of Nov 13, 2026, price $0.0572). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Rapid Dose Therapeutics Corp (RDTCF)?
Balance-sheet figures for Rapid Dose Therapeutics Corp (as of Nov 13, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is RDTCF from its 52-week high?
Rapid Dose Therapeutics Corp trades at $0.0572, about 62% below its 52-week high of $0.1500 and 333% above the low of $0.0132 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0538 is for.
Which stocks are comparable to Rapid Dose Therapeutics Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rapid Dose Therapeutics Corp stock attractive at the current price?
The data as of Nov 13, 2026: price $0.0572, calculated fair value $0.0538 (−6%), Quality Score 23/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9% above its aggregate fair value. Rapid Dose Therapeutics Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rapid Dose Therapeutics Corp (RDTCF)?
The closing price on Nov 9, 2026 was $0.0572. Our estimate is $0.0538, about 6% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rapid Dose Therapeutics Corp right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Rapid Dose Therapeutics Corp

How large is the market capitalisation of Rapid Dose Therapeutics Corp (RDTCF)?
The market capitalisation of Rapid Dose Therapeutics Corp is $10.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rapid Dose Therapeutics Corp (RDTCF)?
The price-to-sales ratio of Rapid Dose Therapeutics Corp is 4.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rapid Dose Therapeutics Corp (RDTCF)?
Earnings per share at Rapid Dose Therapeutics Corp are $−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Rapid Dose Therapeutics Corp (RDTCF)?
The net margin of Rapid Dose Therapeutics Corp is −122% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Rapid Dose Therapeutics Corp (RDTCF)?
The return on equity (ROE) of Rapid Dose Therapeutics Corp is −914% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rapid Dose Therapeutics Corp (RDTCF)?
On an EBIT basis the return on assets of Rapid Dose Therapeutics Corp is −46.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rapid Dose Therapeutics Corp (RDTCF)?
The operating margin of Rapid Dose Therapeutics Corp is −242% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rapid Dose Therapeutics Corp (RDTCF)?
Revenue at Rapid Dose Therapeutics Corp is growing −67.8% versus a year earlier (3y avg +56.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Rapid Dose Therapeutics Corp (RDTCF) generate?
The free cash flow of Rapid Dose Therapeutics Corp is −C$271K (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Rapid Dose Therapeutics Corp (RDTCF) carry?
The net debt of Rapid Dose Therapeutics Corp is C$5.1M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Rapid Dose Therapeutics Corp in the live analysis

One click puts Rapid Dose Therapeutics Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.